Syros Pharmaceuticals Q3 EPS $(1.43) May Not Be Comparable To $(1.14) Estimate, Sales $3.76M Miss $3.94M Estimate
Portfolio Pulse from Benzinga Newsdesk
Syros Pharmaceuticals (NASDAQ:SYRS) reported Q3 EPS of $(1.43), missing the $(1.14) estimate by 25.44%, and sales of $3.76M, missing the $3.94M estimate by 4.52%. This reflects a 55.45% increase in EPS losses and a 3.32% decrease in sales from the same period last year.
November 14, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Syros Pharmaceuticals reported a larger-than-expected Q3 EPS loss and a slight miss in sales, indicating potential negative short-term impact on its stock price.
The reported EPS of $(1.43) is significantly lower than the estimated $(1.14), missing by 25.44%, which is a substantial negative surprise for investors. Additionally, the sales miss, although smaller, could further erode investor confidence. Historically, such earnings misses can lead to short-term declines in stock price as the market adjusts to the new information.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100